AMG 151 Amgen Protocol Number 20100761

Summary

AMG 151 Amgen Protocol Number 20100761 is a clinical trial^[1].

Key Facts

• AMG 151 Amgen Protocol Number 20100761 is in the country of Czech Republic^[2].
• AMG 151 Amgen Protocol Number 20100761 is in the country of Estonia^[3].
• AMG 151 Amgen Protocol Number 20100761 is in the country of Poland^[4].
• AMG 151 Amgen Protocol Number 20100761 is in the country of United States^[5].
• AMG 151 Amgen Protocol Number 20100761's instance of is recorded as clinical trial^[6].
• AMG 151 Amgen Protocol Number 20100761's start time is recorded as +2011-09-30T00:00:00Z^[7].
• AMG 151 Amgen Protocol Number 20100761's end time is recorded as +2012-10-31T00:00:00Z^[8].
• AMG 151 Amgen Protocol Number 20100761's sponsor is recorded as Amgen^[9].
• AMG 151 Amgen Protocol Number 20100761's main subject is recorded as diabetes^[10].
• AMG 151 Amgen Protocol Number 20100761's number of participants is recorded as {'unit': '1', 'amount': '+236'}^[11].
• AMG 151 Amgen Protocol Number 20100761's title is recorded as A Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of AMG 151 in Subjects With Type 2 Diabetes Mellitus^[12].
• AMG 151 Amgen Protocol Number 20100761's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[13].
• AMG 151 Amgen Protocol Number 20100761's ClinicalTrials.gov ID is recorded as NCT01464437^[14].
• AMG 151 Amgen Protocol Number 20100761's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+75'}^[15].
• AMG 151 Amgen Protocol Number 20100761's research intervention is recorded as metformin^[16].
• AMG 151 Amgen Protocol Number 20100761's clinical trial phase is recorded as phase II clinical trial^[17].
• AMG 151 Amgen Protocol Number 20100761's research subject recruitment status is recorded as completed^[18].
• AMG 151 Amgen Protocol Number 20100761's study type is recorded as interventional study^[19].